Use of n-ethyl-2-(5-fluoro-1h-indol-3-yl)-n-methylethan-1-amine or a salt thereof to treat mood disorders.
CL202601662A1Pending Publication Date: 2026-07-24GILGAMESH PHARMACEUTICALS INC
View PDF -1 Cites 0 Cited by
Patent Information
- Application Number
- CL202601662
- Authority / Receiving Office
- CL · CL
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-11-22
- Filing Date
- 2026-05-20
- Publication Date
- 2026-07-24
Abstract
The present description relates to a method for treating a patient with a mood disorder, comprising administering to a subject in need a pharmaceutical composition comprising a base compound consisting substantially of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine or a pharmaceutically acceptable salt thereof in a specific dosage regimen. (Bretisilocin<!--TgQPHd||[]--> or 5-Fluoro-MET)
Need to check novelty before this filing date? Find Prior Art